Individuals with higher-than-average melatonin concentrations are less likely to develop cancer. In cancer patients, psychosomatic coping patterns and treatment side effects are essential indicators of cancer prevention and immune system deterioration. This study focused on changes in the urinary melatonin concentration, life resilience, sleep quality in bladder cancer patients before, and three months after treatment.
A controlled before-and-after study was performed. The subjects were patients who were previously diagnosed with bladder cancer and had received treatment. Data from 23 subjects were analyzed.
The results showed a significant difference in the melatonin concentration before and after treatment. The melatonin concentration in 16 patients increased after treatment. The mean PSQI score after treatment was 6.435. These results represent the improved sleep quality in patients post-treatment.
The study concluded that after treatment, the urinary melatonin concentration and sleep quality (PSQI) improved, both of which were statistically significant in bladder cancer patients. Consequently, bladder cancer treatment should be initiated as soon as possible. There was no significant difference in overall life resilience before and after treatment, possibly because elderly individuals have strong personality traits and emotional stability and are not easily affected by life events or stress.
Reference: https://journals.sagepub.com/doi/full/10.1177/1756287220940870
